MGTX News and Press, MeiraGTx Holdings plc From 11/05/20

MeiraGTx (MGTX): Q3 GAAP EPS of -$0.17 beats by $0.52.Revenue of $5.1M (+42.5% Y/Y) beats by $4.19M.Press Release For further details see: MeiraGTx EPS beats by $0.52, beats on revenue

MeiraGTx preparing to initiate Phase 3 trial of AAV-RPGR Plasmid production facility expected to be completed year-end 2020 LONDON and NEW YORK,, Nov. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrate...

LONDON and NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that twelve-month results from the ongoing Phase 1/2 clinical trial ( NCT03252847 ) of AAV-RPGR,...

Johnson & Johnson (JNJ) unit, Janssen Pharmaceuticals and licensor MeiraGTx Holdings (MGTX) announce nine-month data from the ongoing Phase 1/2 clinical trial of AAV-RPGR, an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors head into next week with a few October surprises already in the books. Stimulus drama and further developments...

Data presented a t EURETINA 2020 Virtual Congress show sustained improvements in retinal sensitivity at nine months S ignificant improvement s were also demonstrated in the time taken to walk through a vision-...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

LONDON and NEW YORK, Sept. 28, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Chardan 4 th...

LONDON and NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced nine-month results from the ongoing Phase 1/2 clinical trial ( NCT03252847 ) of AAV-RPGR, an in...

Company Overview MeiraGTx ( MGTX ) is a clinical-stage gene therapy company targeting serious conditions with no existing curative options or even acceptable therapeutic approaches. It has four clinical-stage programs for ocular conditions, one for Parkinson's disease, and one for radiatio...